30
Aug 2026
Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers and most won't need to continue treatment long-term, according to a study funded by the British Heart Foundation and presented at the European Society of Cardiology Congress in Munich.
29
Aug 2026
Remotely delivered exercise-based cardiac rehabilitation, when added to center-based programs, resulted in a similar number of completed sessions as center-based programs only, according to results presented in a Hot Line session today at ESC Congress 2026.
29
Aug 2026
A rapid pathway for diagnosing heart attacks in the emergency department (ED) was as safe as a slower pathway but neither reduced the length of time patients spent in the ED nor increased direct discharge from the ED.
29
Aug 2026
Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional angiography in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
29
Aug 2026
A registry-based digital strategy that identified untreated patients and invited them to a telephone consultation more than doubled implementation of an effective type of heart failure treatment.
29
Aug 2026
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts of the body and continued to progress despite previous treatment.
29
Aug 2026
Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.
29
Aug 2026
Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.
29
Aug 2026
Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding.
29
Aug 2026
Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
